Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries-Reference-Cited by-同舟云学术

Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries

Published:2021-04-16 Issue:7 Volume:17 Page:2298-2310
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Kumar Prashant¹,Shukla Ravi S.¹,Patel Ashaben¹,Pullagurla Swathi R.¹,Bird Christopher¹,Ogun Oluwadara¹,Kumru Ozan S.¹,Hamidi Ahd²,Hoeksema Femke²,Yallop Christopher²,Bines Julie E.³⁴,Joshi Sangeeta B.¹,Volkin David B.¹

Affiliation:

1. Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA

2. Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The Netherlands

3. Murdoch Children’s Research Institute, Department of Paediatrics, University of Melbourne, Parkville, Australia

4. Department of Gastroenterology and Clinical Nutrition, Royal Children’s Hospital, Parkville, Australia

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1885279

Reference41 articles.

1. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000–2013

2. World Health Organization. WHO recommends use of rotavirus vaccines in all national immunization programmes. [accessed 2020 Sept 23]. http://www.who.int/immunization/newsroom/newsstory_rotavirus_vaccines_immunization_programmes/en/.

3. Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward

4. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth

5. Rotavirus vaccines in developing countries: The potential impact, implementation challenges, and remaining questions

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA’s Purple Book;AAPS PharmSciTech;2024-04-18

2. Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate;Molecular Therapy - Methods & Clinical Development;2023-09

3. Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli;Journal of Pharmaceutical Sciences;2023-07

4. Analytical considerations to support expeditious formulation development of vaccines;Bioanalysis;2023-06

5. Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate;2023-03-13